Jove RL - Search Results

1

Messina JL, Yu H, Riker AI, Munster PN, Jove RL, Daud AI. Messina JL, et al. Among authors: jove rl. Cancer Control. 2008 Jul;15(3):196-201. doi: 10.1177/107327480801500302. Cancer Control. 2008. PMID: 18596671 Free article.

2

Roles of activated Src and Stat3 signaling in melanoma tumor cell growth.

Niu G, Bowman T, Huang M, Shivers S, Reintgen D, Daud A, Chang A, Kraker A, Jove R, Yu H. Niu G, et al. Oncogene. 2002 Oct 10;21(46):7001-10. doi: 10.1038/sj.onc.1205859. Oncogene. 2002. PMID: 12370822

3

Immunotherapy as part of a multidisciplinary approach to melanoma treatment.

Riker AI, Jove R, Daud AI. Riker AI, et al. Front Biosci. 2006 Jan 1;11:1-14. doi: 10.2741/1775. Front Biosci. 2006. PMID: 16146709 Review.

4

Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma.

Homsi J, Cubitt CL, Zhang S, Munster PN, Yu H, Sullivan DM, Jove R, Messina JL, Daud AI. Homsi J, et al. Melanoma Res. 2009 Jun;19(3):167-75. doi: 10.1097/CMR.0b013e328304974c. Melanoma Res. 2009. PMID: 19434004

5

Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo.

Niu G, Heller R, Catlett-Falcone R, Coppola D, Jaroszeski M, Dalton W, Jove R, Yu H. Niu G, et al. Cancer Res. 1999 Oct 15;59(20):5059-63. Cancer Res. 1999. PMID: 10537273

6

Signal Transducers and Activators of Transcription: Novel Targets for Anticancer Therapeutics.

Bowman T, Yu H, Sebti S, Dalton W, Jove R. Bowman T, et al. Cancer Control. 1999 Oct;6(5):427-435. Cancer Control. 1999. PMID: 10758575

7

The STATs of cancer--new molecular targets come of age.

Yu H, Jove R. Yu H, et al. Nat Rev Cancer. 2004 Feb;4(2):97-105. doi: 10.1038/nrc1275. Nat Rev Cancer. 2004. PMID: 14964307 Review. No abstract available.

8

Overexpression of a dominant-negative signal transducer and activator of transcription 3 variant in tumor cells leads to production of soluble factors that induce apoptosis and cell cycle arrest.

Niu G, Shain KH, Huang M, Ravi R, Bedi A, Dalton WS, Jove R, Yu H. Niu G, et al. Cancer Res. 2001 Apr 15;61(8):3276-80. Cancer Res. 2001. PMID: 11309279

9

Combination therapy with AG-490 and interleukin 12 achieves greater antitumor effects than either agent alone.

Burdelya L, Catlett-Falcone R, Levitzki A, Cheng F, Mora LB, Sotomayor E, Coppola D, Sun J, Sebti S, Dalton WS, Jove R, Yu H. Burdelya L, et al. Mol Cancer Ther. 2002 Sep;1(11):893-9. Mol Cancer Ther. 2002. PMID: 12481410

10

Targeting STAT3 affects melanoma on multiple fronts.

Kortylewski M, Jove R, Yu H. Kortylewski M, et al. Cancer Metastasis Rev. 2005 Jun;24(2):315-27. doi: 10.1007/s10555-005-1580-1. Cancer Metastasis Rev. 2005. PMID: 15986140 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

236 results

Search Page

Filters